secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001104659-24-010087
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals transfers listing to Nasdaq Capital Market effective Jan 19, 2024
--------------------------------------------------------------------------------

- Nasdaq approved transfer from Global Market to Capital Market; effective Jan 19, 2024.
- Company had previously received extension until April 16, 2024 to regain compliance.
- Transfer is a condition of the extension; avoids immediate delisting.
- Listing on Capital Market subject to continued compliance with rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924010087/0001104659-24-010087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924010087/tm245109d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-010087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer